ASX:SOM SomnoMed (SOM) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About SomnoMed Stock (ASX:SOM) 30 days 90 days 365 days Advanced Chart Get SomnoMed alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolume95,124 shsAverage VolumeN/AMarket Capitalization$136.15 millionP/E RatioN/ADividend Yield2.25%Price TargetN/AConsensus RatingN/A Company OverviewSomnoMed Limited, together with its subsidiaries, engages in the production and sale of devices for the oral appliances for the treatment of sleep related disorders in Europe, North America, and the Asia Pacific region. Its flagship product SomnoDent Avant, as well as SomnoDent Classic, SomnoDent Flex, and SomnoDent Fusion are offered for the treatment of obstructive sleep apnea. The company also offers SomMorning Repositioner, a product designed to help return patient's mandible back to its pre-treatment centric position; SomnoBrux splint, a custom fit, acrylic splint for patient's upper teeth designed to protect teeth from grinding and scraping during Bruxism; and SomTabs are cleaning tablets, developed to clean oral appliances safely and effectively. In addition, it also provides sleep test at home under the Sunrise brand name. The company was incorporated in 1987 and is headquartered in Crows Nest, Australia.Read More… Receive SOM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for SomnoMed and its competitors with MarketBeat's FREE daily newsletter. Email Address SOM Stock News HeadlinesSomnoMed Addresses Impact of New US Tariffs on OperationsApril 7, 2025 | tipranks.comSomnoMed Strengthens Leadership with New Director AppointmentJanuary 19, 2025 | tipranks.comWhat President Trump’s Executive Order 14154 means for your moneyNearly $3 trillion disappeared from the stock market on Thursday morning. According to Whitney Tilson - a former hedge fund manager who predicted the dotcom crash, the housing crisis, and the 2022 tech stock bloodbath - a little-known executive order from the President's first day in office could spark a paradigm-shift that will likely catch millions of Americans off guard.May 1, 2025 | Stansberry Research (Ad)SomnoMed Appoints Andrew Price as New Director to Enhance Global OperationsJanuary 19, 2025 | tipranks.comSomnoMed Limited Announces AGM Resolutions ApprovalNovember 27, 2024 | tipranks.comSomnoMed Projects Growth and Appoints New CFONovember 26, 2024 | tipranks.comSomnoMed Limited: Evaluating Investment Risks and OpportunitiesNovember 26, 2024 | tipranks.comSomnoMed Limited Sees Growth and Innovation in 2024November 26, 2024 | tipranks.comSee More Headlines Industry, Sector and Symbol Stock ExchangeASX SectorMedical Industry Medical Devices Sub-IndustryN/A Current SymbolASX:SOM CIKN/A Websomnomed.com Phone61 2 9467 0400FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)A($0.10) Trailing P/E RatioN/A Forward P/E RatioN/A P/E Growth-0.09Net Income$-12,240,000.00 Net Margins-13.36% Pretax MarginN/A Return on Equity-32.68% Return on Assets-7.86% Debt Debt-to-Equity Ratio14.92 Current Ratio1.76 Quick Ratio1.05 Sales & Book Value Annual Sales$91.65 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow7.61 Book ValueA$0.37 per share Price / BookN/AMiscellaneous Outstanding Shares216,110,000Free FloatN/AMarket Cap$136.15 million OptionableNot Optionable Beta1.37 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.Get This Free Report This page (ASX:SOM) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredElon Musk’s next move from the Oval Office?No one is closer to President Trump than Tesla CEO Elon Musk. He's been dubbed Trump's "first buddy." Tr...Weiss Ratings | SponsoredElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredThis Is How Empires FallThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | Sponsored"I'm risking my reputation on this"I've stayed quiet for too long, but after everything I've uncovered about what's brewing in the 2025 crypto ma...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SomnoMed Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share SomnoMed With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.